Skip to main content
SpringerLink
Log in

Select the appropriate treatment regimen to improve morbidity and mortality in immunocompromised paediatric patients with invasive candidiasis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Fisher BT, Zaoutis TE. Treatment of invasive candidiasis in immunocompromised pediatric patients. Pediatr Drugs 2008; 10(5): 281–98

    Article  Google Scholar 

  2. Rüping MJGT, Vehreschild, JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008; 68(14): 1941–62

    Article  PubMed  Google Scholar 

  3. Zaoutis TE, Foraker E, McGowan KL, et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children’s hospitals. Diagn Microbiol Infect Dis 2005 Aug; 52(4): 295–8

    Article  PubMed  CAS  Google Scholar 

  4. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000 Nov; 31(5): 1155–63

    Article  PubMed  CAS  Google Scholar 

  5. Walsh TJ, Hiemenz JW, scibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998 Jun; 26(6): 1383–96

    Article  PubMed  CAS  Google Scholar 

  6. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001 Feb; 20(2): 77–82

    PubMed  CAS  Google Scholar 

  7. Graybill JR, Tollemar J, Torres-Rodriguez JM, et al. Antifungal compounds: controversies, queries and conclusions. Med Mycol 2000; 38Suppl. 1: 323–33

    PubMed  CAS  Google Scholar 

  8. Anaissie EJ, White M, Uzun O, et al. Amphotericin B lipid complex versus amphotericin B for the treatment of invasive candidiasis: a prospective, randomized, multicenter trial [abstract no. LM21]. 35th Interscience Conference on Antimicrobial Agents Chemotherapy; 1995 Sep 17–20; San Francisco (CA): 330

  9. Walsh TJ, Adamson PC, seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005 Nov; 49(11): 4536–45

    Article  PubMed  CAS  Google Scholar 

  10. seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005 Aug; 49(8): 3317–24

    Article  PubMed  CAS  Google Scholar 

  11. Benjamin Jr DK, Driscoll T, scibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006 Feb; 50(2): 632–8

    Article  PubMed  CAS  Google Scholar 

  12. Zaoutis TE, Benjamin DK, Steinbach WJ. Antifungal treatment in pediatric patients. Drug Resist Updat 2005 Aug; 8(4): 235–45

    Article  PubMed  CAS  Google Scholar 

  13. European Medicine Agency. Assessment report for mycamine [online]. Available from URL: http://www.emea.europa.eu [Accessed 2009 Mar 20]

  14. Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000 Aug; 46(2): 171–9

    Article  PubMed  CAS  Google Scholar 

  15. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4, 169 clinical isolates of Candida spp. and Cryptococcusneoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004 Mar; 48(3): 201–5

    Article  PubMed  CAS  Google Scholar 

  16. Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005 Dec; 43(12): 5848–59

    Article  PubMed  CAS  Google Scholar 

  17. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006 Mar; 44(3): 819–26

    Article  PubMed  CAS  Google Scholar 

  18. Lortholary O, Dannaoui E, Raoux D, et al. In vitro susceptibility to posaconazole of 1903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing. Antimicrob Agents Chemother 2007 Sep; 51(9): 3378–80

    Article  PubMed  CAS  Google Scholar 

  19. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, et al. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis 1998 Jun; 26(6): 1270–8

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Select the appropriate treatment regimen to improve morbidity and mortality in immunocompromised paediatric patients with invasive candidiasis. Drugs Ther. Perspect 25, 10–13 (2009). https://doi.org/10.2165/0042310-200925070-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/0042310-200925070-00003

Search

Navigation